Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

EPA's Ethylene Oxide Plan May Hinder Other Air Toxics Regs No Photo Available

Gautama Mehta

A new proposal from the U.S. Environmental Protection Agency to weaken emission standards for a medical sterilizer could have broader ... (more story)

Eye On ERISA: A Chat With King & Spalding's Darren Shuler No Photo Available

Kellie Mejdrich

Increased scrutiny of health plans and the high costs of care are fueling a litigation uptick that's coming not just from plan partici... (more story)

Legislative Update: Cannabis And Psychedelics Bill Roundup No Photo Available

Sam Reisman

Virginia lawmakers last week gave final approval to legislation that would tax and regulate the sale of adult-use cannabis, Georgia le... (more story)